Turnstone Biologics Corp. financial data

Symbol
TSBX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
9310 Athena Circle, Suite 300, La Jolla, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 570 %
Debt-to-equity 21.5 %
Return On Equity -106 % -205%
Return On Assets -86.9 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.1M shares +1.25%
Common Stock, Shares, Outstanding 23.1M shares +0.15%
Entity Public Float 0 USD
Common Stock, Value, Issued 23K USD 0%
Weighted Average Number of Shares Outstanding, Basic 23M shares +32.4%
Weighted Average Number of Shares Outstanding, Diluted 23M shares +32.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 61.4M USD +1.78%
General and Administrative Expense 17.6M USD -17.1%
Operating Income (Loss) -79M USD +2.97%
Nonoperating Income (Expense) 3.59M USD -67%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -75.4M USD -2.86%
Income Tax Expense (Benefit) -963K USD -2373%
Net Income (Loss) Attributable to Parent -74.4M USD -42%
Earnings Per Share, Basic -0.74 USD/shares +26%
Earnings Per Share, Diluted -0.74 USD/shares +26%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24.1M USD -37.8%
Cash, Cash Equivalents, and Short-term Investments 77.8M USD
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 2.03M USD -23.1%
Assets, Current 51.1M USD -57%
Property, Plant and Equipment, Net 5.08M USD -37%
Operating Lease, Right-of-Use Asset 1.39M USD -56.7%
Other Assets, Noncurrent 873K USD -27.4%
Assets 58.5M USD -55.5%
Accounts Payable, Current 560K USD -76.5%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 13.6M USD +4.3%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 259K USD -84.7%
Other Liabilities, Noncurrent 940K USD -64.4%
Liabilities 14.8M USD -14.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -196K USD +18.7%
Retained Earnings (Accumulated Deficit) -235M USD -46.4%
Stockholders' Equity Attributable to Parent 43.6M USD -61.7%
Liabilities and Equity 58.5M USD -55.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.5M USD -1.69%
Net Cash Provided by (Used in) Investing Activities 14.1M USD -14.6%
Common Stock, Shares Authorized 490M shares 0%
Common Stock, Shares, Issued 23.1M shares +0.15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.37M USD -127%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.2M USD -37.7%
Deferred Tax Assets, Valuation Allowance 46.8M USD +25.6%
Deferred Tax Assets, Gross 48.1M USD +20%
Operating Lease, Liability 1.7M USD -53.8%
Payments to Acquire Property, Plant, and Equipment 144K USD -83.6%
Lessee, Operating Lease, Liability, to be Paid 1.74M USD -54.8%
Property, Plant and Equipment, Gross 13.1M USD -9.37%
Operating Lease, Liability, Current 1.44M USD -27.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 104K USD -90.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.11M USD -47.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure +20.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 43K USD -75.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.2M USD +156%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Additional Paid in Capital 279M USD +1.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.2M USD -28.6%
Share-based Payment Arrangement, Expense 4.06M USD -14.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%